- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04511078
Phase II Panitumumab-IRDye800 in Head & Neck Cancer
Phase II Open-Label Study Evaluating Panitumumab-IRDye800 as an Optical Imaging Agent to Detect Head and Neck Cancer During Surgical Procedures
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Head and neck squamous cell carcinoma tumors can be difficult to visualize intraoperatively. Most primary oral cavity cancers and previously irradiated head and neck cancers require surgical resection for definitive treatment. Currently, tumor margins are determined intraoperatively by a combination of palpation, visual inspection, and microscopic assessment frozen tissue sections. Difficulty in assessing intraoperative tumor margins of primary head and neck cancers makes resection inexact -the incidence of involved or close surgical margins in head and neck cancer patients approaches 40% on histopathological review. Failure to obtain a complete tumor resection results in significantly worse outcomes in head and neck cancer patients. With the exception of previously untreated tongue cancers, assessment of tumor margins by intraoperative palpation is limited because tumors are adjacent to bone or cartilage (larynx), in deep structures, or in previously irradiated tissues. More accurate assessment of tumor extent could limit the ablative defect size and improve outcomes.
Intraoperative frozen sections are used to confirm complete resection of tumors. Unfortunately, these have significant deficiencies. Frozen sections 1) require resection of additional normal tissue for assessment, 2) add between 30 and 60 minutes to the operative time, 3) are difficult to interpret in patients with field cancerization or previous irradiation, 4) cannot be performed on bone or calcified cartilage, 5) are reversed on permanent section in approximately 5% of cases and 6) fail to detect close margins (> 5 mm). Finally, and perhaps most importantly, frozen sections are highly accurate if the right tissue is biopsied and sent; however, less than 5% of the wound bed can be assessed by frozen section and this significantly limits the sensitivity of this technique. This sampling error consistently plagues surgeons and pathologists alike.
Identification of margins during resection is difficult because tumors cannot be palpated and the surgeon must rely only on subtle tissue changes when using the operating microscope. Optical imaging is ideally suited to endoscopic and robotic operative approaches since the surgeon is operating from the video monitor and fluorescence can be easily incorporated into the surgeon's view. Importantly, optical imaging is being incorporated into the newest robotic platforms made especially for surgical procedures.
This is a Phase II study of panitumumab-IRDye800CW, which has emerged as the frontrunner in optical imaging. This study will be performed in the context of collaborating, completed, and ongoing dose-escalation Phase 1 clinical trials evaluating the safety of cetuximab-IRDye800 (NCT01987375) and panitumumab-IRDye800 (NCT02415881), respectively, in the same patient population. This study design is the same as our approved Phase I trials, except there will be no dose-escalation. This study design is the standard for Phase II clinical trials in the field of fluorescence-guided surgery.
The investigators saw a limited number of mild side effects with no serious side effects in patients receiving this drug (no infusion reactions, no Grade 2 or higher adverse events, and one Grade 1 adverse event in human patients). In 21% of cases, fluorescence imaging was able to improve surgical decision-making and lead to resection of tumor-containing tissue that would likely not have otherwise been resected. Given that positive margins are the single most important prognostic factor for patients with HNSCC, the potential for this technology to improve margin status has the potential to improve outcomes and survival.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Norma Miller, RN
- Phone Number: (205) 975-6169
- Email: ncmiller@uabmc.edu
Study Locations
-
-
Alabama
-
Birmingham, Alabama, United States, 35233
- Recruiting
- University of Alabama at Birmingham
-
Contact:
- Norma Miller, RN
- Phone Number: 205-975-6169
- Email: ncmiller@uabmc.edu
-
Sub-Investigator:
- Jason Warram, PhD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Biopsy confirmed diagnosis of squamous cell carcinoma of the head and neck
- Diagnosis of any T stage, any subsite within the head and neck that are scheduled to undergo surgical resection. Patients with recurrent disease or a new primary will be allowed.
- Planned standard of care surgery with curative intent for squamous cell carcinoma
- Male or female patients age ≥ 18 years
- Have life expectancy of more than 12 weeks
- Karnofsky performance status of at least 70% or ECOG/Zubrod level 1
Have acceptable hematologic status, coagulation status, kidney function, and liver function including the following clinical results:
- Hemoglobin ≥ 9 gm/dL
- Absolute Neutrophil Count ≥ 1500
- White Blood Cell count > 3000/mm3
- Platelet count ≥ 100,000/mm3
- Serum creatinine ≤ 1.5 times upper reference range
Exclusion Criteria:
- Received an investigational drug within 30 days prior to first dose of panitumumab-IRDye800
- Had within 6 months prior to enrollment: MI, CVA, or uncontrolled CHF
- History of infusion reactions to any monoclonal antibody therapies
- Women who are pregnant or breast-feeding
- Evidence of QT prolongation on pretreatment ECG (greater than 440 ms in males or greater than 450 ms in females)
- Magnesium or potassium lower than the normal institutional values
- Patients receiving Class IA (quinidine, procanamide) or Class III (dofetilide, amiodarone, sotalol) antiarrhythmic agents
- Patients with a history or evidence of interstitial pneumonitis or pulmonary fibrosis
- TSH > 13 micro International Units/mL
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Panitumumab-IRDye800
50 mg infusion of panitumumab-IRDye800 given over 60 minutes
|
single dose infusion of panitumumab-IRDye800CW
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Tumor to background ratio of fluorescence (TBR)
Time Frame: Day 0 through Day 15
|
fluorescence intensity of tumor tissue compared to that of normal surrounding tissue
|
Day 0 through Day 15
|
Collaborators and Investigators
Investigators
- Principal Investigator: Carissa Thomas, MD PhD, University of Alabama at Birmingham
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- IRB-300005079
- UAB 1969 (Other Identifier: O'Neal Comprehensive Cancer Center)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Head and Neck Cancer
-
Robert FerrisAmgenCompletedHead and Neck Cancer | Cancer of Head and Neck | Head Cancer | Neck Cancer | Neoplasms, Head and Neck | Cancer of the Head and Neck | Cancer of Neck | Upper Aerodigestive Tract Neoplasms | Neck Neoplasms | Cancer of the Head | Cancer of the Neck | UADT Neoplasms | Cancer of Head | Head Neoplasms | Head, Neck Neoplasms | Neoplasms, Head and other conditionsUnited States
-
Assiut UniversityRecruitingHead and Neck Cancer | Head and Neck Neoplasms | Cancer of Head and Neck | Neoplasms, Head and Neck | Cancer of the Head and NeckEgypt
-
Mayo ClinicRecruitingCancer Head Neck | Cancer Neck | Cancer, HeadUnited States
-
IRCCS Policlinico S. MatteoNestlé Health Science Spain; Akern SrlCompletedHead-neck CancerItaly
-
University of California, San FranciscoCompleted
-
Chinook Therapeutics, Inc. (formerly Aduro)TerminatedRecurrent Head and Neck Cancer | Metastatic Head and Neck CancerUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)TerminatedHead And Neck CancerUnited States
-
National Cancer Institute (NCI)TerminatedRecurrent Head and Neck Cancer | Metastatic Head and Neck CancerUnited States
-
Radboud University Medical CenterUnknown
-
Centre Oscar LambretUnknownEpidermoid Head and Neck CancerFrance
Clinical Trials on Panitumumab-IRDye800
-
Vanderbilt-Ingram Cancer CenterNational Cancer Institute (NCI)RecruitingHead and Neck Squamous Cell Carcinoma | Recurrent Head and Neck Squamous Cell CarcinomaUnited States
-
Stanford UniversityNot yet recruitingBrain TumorUnited States
-
Eben RosenthalRecruitingStage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Lung Carcinoma | Metastatic Malignant Neoplasm in the LungUnited States
-
Andrei IagaruNational Cancer Institute (NCI); National Institutes of Health (NIH)CompletedSquamous Cell Carcinoma of the Head and Neck | Carcinoma of the Head and NeckUnited States
-
Eben RosenthalNational Cancer Institute (NCI)RecruitingPancreatic AdenocarcinomaUnited States
-
Eben RosenthalNational Institutes of Health (NIH)Active, not recruitingMalignant Glioma | Malignant Brain NeoplasmUnited States
-
University of MichiganCompleted
-
Eben RosenthalNational Cancer Institute (NCI)CompletedHead and Neck Cancer | Head and Neck Squamous Cell Carcinoma | Squamous Cell Carcinoma of the Head and Neck (SCCHN)United States
-
Beijing Institute of Heart, Lung and Blood Vessel...Beijing Tiantan Hospital; Southwest Hospital, China; Nanfang Hospital of Southern... and other collaboratorsUnknown
-
Spanish Cooperative Group for the Treatment of...AmgenCompleted